Several Xarelto Lawsuit Plaintiffs Note Studies Conducted On Drug Which Support Their Claims

BloodThinnerHelp.com reports on the number of lawsuits which have been filed against Xarelto manufacturers and independent studies that have linked the drug to excessive bleeding. To date, there have been well over 2,800 federal cases filed that have been consolidated by the U.S. Judicial Panel on Multidistrict Litigation (JPMDL). The multidistrict litigation (MDL) number 2592 is being overseen by the Honorable Judge Eldon Fallon in Louisiana. There is also a mass tort program in Philadelphia, PA with 550 cases filed against the drug manufacturers.

The blood-thinning drug Xarelto was approved by the U.S. Food and Drug Administration (FDA) in 2011 and was released on the market to treat patients who were susceptible to blood clots and stroke due to hip or knee replacement surgeries, and for various medical conditions such as deep vein thrombosis, pulmonary embolism, and atrial fibrillation. After its release, however, the drug became associated with some possible side effects that proved to be potentially dangerous and life-threatening.

In response to these reports of linked side effects, a number of independent studies were conducted to further investigate claims that were being made that Xarelto caused excessive bleeding, which are now also being used by Xarelto plaintiffs in their cases against the manufacturers of the drug. The first was done by two doctors, Judy Hun and John Hwang, that began to see some patients suffering instances of eye bleeding. After the doctors completed their study they concluded that the eye bleeding was precipitated when those using other more traditional blood thinner medications switched to Xarelto.

Another study done between October 1, 2010, and March 31, 2012, examined the use of three blood thinner drugs, specifically Xarelto, warfarin and Pradaxa in a sample of 46,000 patients. The study's results indicated that there was a much higher risk of bleeding with rivaroxaban (Xarelto) when compared with warfarin.

The Osborne firm is offering free consultations to anyone who suffered injury or hospitalization after a bleed while on Xarelto. Call (866) 425-8902 for more information about this release or the Xarelto litigation.